Financials
Financial year 2025
DIALEX BIOMEDICA SALES from Bilzen-Hoeselt, company number BE0466736977, closed financial year 2025 with a result of € 6.3 million after tax. For that financial year DIALEX BIOMEDICA SALES recorded a gross margin of € 222,791 and equity of € 19.6 million. Compared with financial year 2024, the result moved from € 2.7 million to € 6.3 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 23, 2025.
€ 19.6 million
▲ 36% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 6.3 million
▲ 132% vs 2024
Profit after tax over the fiscal year.
€ 2.5 million
▲ 99% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 1 million paid out
16 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
1.2
Average over the fiscal year, from the social balance sheet.
€ 67,790
▼ 22% vs 2024
€ 56,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 25,083
▼ 40% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 14,048
▼ 2% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 560,628
▲ € 519,723 vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 513,020 | € 511,240 | € 512,887 | - | |
| Gross margin | - | - | - | € 222,791 | |
| Profit after taxes | € 1,776,661 | € 2,462,059 | € 2,709,114 | € 6,281,374 | ▲ 132% |
| Equity | € 9,850,711 | € 11,847,113 | € 14,385,092 | € 19,633,155 | ▲ 36% |
| Total debts | € 744,181 | € 720,506 | € 635,472 | € 1,117,963 | ▲ 76% |
| Cash | € 715,450 | € 312,552 | € 1,238,496 | € 2,459,250 | ▲ 99% |
| Land & buildings | € 2,535,213 | € 2,436,131 | € 2,322,998 | € 2,202,943 | ▼ 5% |
| Retained profit | € 9,830,711 | € 11,827,113 | € 14,365,092 | € 19,613,155 | ▲ 37% |
| Dividend | € 984,143 | € 465,658 | € 171,135 | € 1,033,311 | ▲ € 862,177 |
| Bank debt | € 676,988 | € 621,507 | € 565,153 | € 0 | ▼ 100% |
| Balance sheet total | € 10,594,893 | € 12,567,619 | € 15,020,564 | € 20,751,119 | ▲ 38% |
| Employees (FTE) | 0.1 | 1.2 | 1.2 | 1.2 |
Key figures of DIALEX BIOMEDICA SALES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.
What happened to DIALEX BIOMEDICA SALES?
What happened at DIALEX BIOMEDICA SALES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 6.3 million (▲ 132% vs 2024). Source: NBB ↗
- Michaël Barthels became a director. NBB
- New establishment in Hasselt. KBO
- Start of the company according to the CBE. KBO
In short
From € 1.8 million profit in 2022 to € 6.3 million profit in 2025.
Paid € 928,920 in corporate taxes since 2022.
Best year ever: 2025, with € 6.3 million profit.
On average € 185,700 of value added per employee in 2025.
A new publication or filing at DIALEX BIOMEDICA SALES? We notify you, reason included.
Follow DIALEX BIOMEDICA SALESDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind DIALEX BIOMEDICA SALES is Michaël Barthels. It owns 99.8% of Dialex Biomedica itself.
Directors
According to the 2025 annual accounts
Michaël Barthels
Director
since 2005
Establishments
Establishment units
Physical locations of this company
Caetsbeekstraat 1
3740 Bilzen-Hoeselt
Luikersteenweg 140A box 2
3500 Hasselt
Active since 7 October 1999
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0466.736.977
- VAT number
- BE 0466.736.977
- Registered office
- Caetsbeekstraat 1, 3740 Bilzen-Hoeselt
- Names & denominations
- DIALEX BIOMEDICA SALES
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 25 August 1999
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Handelsbemiddeling in de groothandel in andere specifieke goederen
Activiteiten van holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen
Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen
Ontwikkeling van residentiële bouwprojecten
Verhuur en exploitatie van terreinen
+3